Response assessment to neoadjuvant therapy in soft tissue sarcomas: using CT texture analysis in comparison to tumor size, density, and perfusion

2014 ◽  
Vol 40 (6) ◽  
pp. 1705-1712 ◽  
Author(s):  
Fang Tian ◽  
Koichi Hayano ◽  
Avinash R. Kambadakone ◽  
Dushyant V. Sahani
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Texture Analysis ◽  
Tumor Size ◽  
Soft Tissue Sarcomas ◽  
Response Assessment ◽  
Ct Texture Analysis

scholarly journals Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2061
Author(s):  
Mateusz Jacek Spałek ◽  
Katarzyna Kozak ◽  
Anna Małgorzata Czarnecka ◽  
Ewa Bartnik ◽  
Aneta Borkowska ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Treatment Options ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Therapy Response ◽  
Response Assessment ◽  
Treatment Type ◽  
Therapy Response Assessment

Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks. Finally, we summarize current recommendations of the STS neoadjuvant therapy response assessment.

Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 10017-10017
Author(s):  
V. Evilevitch ◽  
W. A. Weber ◽  
W. D. Tap ◽  
K. Chow ◽  
M. Allen-Auerbach ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Tumor Size ◽  
Fdg Pet ◽  
Soft Tissue Sarcomas ◽  
High Grade ◽  
Fdg Uptake ◽  
Histopathologic Response ◽  
Pet Ct ◽  
Fdg Pet Ct

10017 Background: Change in size by RECIST (Response Evaluation Criteria in Solid Tumors) has been the standard to assess response to therapy in non-GIST soft tissue sarcomas (STS). Although recent studies have demonstrated that Positron Emission Tomography with F18-fluorodeoxyglucose (FDG-PET) may be used to assess response, there has not been a direct comparison between these modalities. The aim of this study was to prospectively evaluate whether a change in quantitative FDG-PET or a change in size [computed tomography(CT)] was more accurate at predicting histopathologic response to neoadjuvant therapy in patients with high grade STS using a combined FDG-PET/CT scan. Methods: From 1/05 - 12/06 58 patients with resectable biopsy proven high grade STS scheduled to undergo neoadjuvant chemotherapy were prospectively enrolled in this study. Patients underwent FDG-PET/CT prior to and after neoadjuvant treatment (prior to surgery). Tumor FDG-uptake was quantified by standardized uptake values (SUV). Changes in tumor size were quantified according to RECIST. Following tumor resection, response was assessed histopathologically. Patients with = 10% viable tumor cells were classified as responders. To date, 36 patients have completed the study and are the subject of this analysis. Results: In histopathologic responders (n=10, 28%), reduction of tumor FDG-uptake was significantly greater (-64%) than in histopathologic non-responders (-37%), (p=0.005). Using a 50% decrease in tumor SUV as a threshold value resulted in a sensitivity of 90% and a specificity of 58% for assessment of histopathologic response (p=0.01). Response assessment per RECIST showed no significant correlation with histopathologic response (sensitivity 20%, specificity 89%, p=0.4). There was no correlation between changes in tumor size and histopathologic response (area under the ROC curve = 0.6, p=0.1). Conclusions: In patients with high grade STS, quantitative FDG-PET was significantly more accurate than size based criteria for assessment of histopathologic response to neoadjuvant therapy. FDG-PET should be considered as a modality to monitor treatment response is patients with high grade STS. No significant financial relationships to disclose.

scholarly journals 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas

2019 ◽  
Vol 60 (11) ◽  
pp. 1537-1542 ◽  
Author(s):  
Johannes Grueneisen ◽  
Benedikt Schaarschmidt ◽  
Aydin Demircioglu ◽  
Michal Chodyla ◽  
Ole Martin ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Fdg Pet ◽  
Soft Tissue Sarcomas ◽  
Therapy Response ◽  
Response Assessment ◽  
Isolated Limb Perfusion ◽  
Limb Perfusion ◽  
Therapy Response Assessment ◽  
18F Fdg

Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas

2001 ◽  
Vol 19 (13) ◽  
pp. 3203-3209 ◽  
Author(s):  
Fritz C. Eilber ◽  
Gerald Rosen ◽  
Jeffery Eckardt ◽  
Charles Forscher ◽  
Scott D. Nelson ◽  
...  
Keyword(s):  
Overall Survival ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Neoadjuvant Therapy ◽  
Independent Predictor ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
High Grade ◽  
Recurrence Rates ◽  
Pathologic Assessment

PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. PATIENTS AND METHODS: Four hundred ninety-six patients with intermediate- to high-grade extremity soft tissue sarcomas received protocol neoadjuvant therapy. All patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tumor necrosis in the resected specimens. RESULTS: The 5- and 10-year local recurrence rates for patients with ≥ 95% pathologic necrosis were significantly lower (6% and 11%, respectively) than the local recurrence rates for patients with less than 95% pathologic necrosis (17% and 23%, respectively). The 5- and 10-year survival rates for the patients with ≥ 95% pathologic necrosis were significantly higher (80% and 71%, respectively) than the survival rates for the patients with less than 95% pathologic necrosis (62% and 55%, respectively). Patients with less than 95% pathologic necrosis were 2.51 times more likely to develop a local recurrence and 1.86 times more likely to die of their disease as compared with patients with ≥ 95% pathologic necrosis. The percentage of patients who achieved ≥ 95% pathologic necrosis increased to 48% with the addition of ifosfamide as compared with 13% of the patients in all the other protocols combined. CONCLUSION: Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. A complete pathologic response (≥ 95% pathologic necrosis) correlated with a significantly lower rate of local recurrence and improved overall survival.

Impact of neoadjuvant therapy on histopathologic response and survival in patients with primary high-grade retroperitoneal soft tissue sarcomas

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 10510-10510
Author(s):  
T. R. Donahue ◽  
M. W. Kattan ◽  
S. D. Nelson ◽  
W. D. Tap ◽  
F. R. Eilber ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Soft Tissue Sarcomas ◽  
High Grade ◽  
Histopathologic Response

Tumor size/symptom duration ratio as a prognostic factor in patients with high-grade soft tissue sarcomas

1988 ◽  
Vol 24 (10) ◽  
pp. 1583-1588 ◽  
Author(s):  
Wlodzimierz Ruka ◽  
Lawrence J. Emrich ◽  
Deborah L. Driscoll ◽  
Constantine P. Karakousis
Keyword(s):  
Prognostic Factor ◽  
Soft Tissue ◽  
Tumor Size ◽  
Soft Tissue Sarcomas ◽  
Symptom Duration ◽  
High Grade

Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size

2009 ◽  
Vol 27 (3) ◽  
pp. 371-376 ◽  
Author(s):  
Andrea Ferrari ◽  
Rosalba Miceli ◽  
Cristina Meazza ◽  
Elena Zaffignani ◽  
Alessandro Gronchi ◽  
...  
Keyword(s):  
Body Size ◽  
Soft Tissue ◽  
Tumor Size ◽  
Soft Tissue Sarcomas ◽  
Childhood And Adolescence ◽  
Significant Prognostic Factor ◽  
Tumor Diameter ◽  
Cox Models ◽  
Histologic Subtype ◽  
Prognostic Effect

Purpose Tumor size is a key prognostic variable for soft tissue sarcomas (STS), and a tumor diameter of 5 cm is generally used as a cutoff for risk grouping purposes. This study aimed to investigate the prognostic effect of tumor size on overall survival and whether such an effect was influenced by the patient's size, expressed as body-surface area (BSA), in a series of 553 pediatric patients with localized STS. Patients and Methods Multivariable Cox models were used in which the effect of tumor size was adjusted for patients age, tumor site, histologic subtype, and Intergroup Rhabdomyosarcoma Study grouping, and the interaction between size and BSA was included. Results Tumor size was confirmed as a significant prognostic factor. Interaction between size and BSA meant that, for a given tumor size, the mortality increased from the larger to the smaller BSA. Conversely, the mortality risk associated with a patient with a BSA of 1.75 m2 and a 5-cm tumor was the same as for a 0.6 m2 child with a 2.8-cm tumor. Conclusion Tumor and body size are jointly informative on outcome. The risk associated with a given tumor size is not the same in patients of different body size, so it may be wrong to use the same 5-cm cutoff for tumor size in risk stratification.

Neoadjuvant therapy for soft tissue sarcomas

Cancer ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2338-2340 ◽  
Author(s):  
Charles R. Scoggins
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document